{"gene":"CCL3","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1995,"finding":"CCL3 (MIP-1α) is required for virus-induced inflammatory responses in vivo: CCL3-null mice are resistant to Coxsackievirus-induced myocarditis and show reduced pneumonitis with delayed viral clearance after influenza infection, demonstrating CCL3 is an essential mediator of inflammatory cell recruitment during viral infection.","method":"Gene knockout (CCL3-/- mice), viral infection models (Coxsackievirus, influenza), histopathology","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — clean KO with specific phenotypic readouts, foundational study replicated across two viral models","pmids":["7667639"],"is_preprint":false},{"year":1993,"finding":"CCL3 (LD78) signals through a G protein-coupled receptor (identified as HM145/CCR1) to decrease cAMP accumulation and induce calcium influx in stable transfectants, establishing functional receptor coupling.","method":"Receptor cloning by PCR, stable transfection, cAMP and calcium flux assays","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 1 — in vitro functional reconstitution with stable transfectants, multiple signaling readouts","pmids":["7505609"],"is_preprint":false},{"year":1999,"finding":"The LD78beta isoform of CCL3 has a proline at position 2 that confers ~6-fold enhanced binding affinity to CCR5 and ~15–20-fold enhanced affinity to D6 receptor compared to LD78alpha, and displays markedly higher HIV-1 suppressive activity, establishing the N-terminal residue as a critical determinant of receptor binding and antiviral potency.","method":"Receptor binding assays, site-directed mutagenesis (Pro2), HIV-1 suppression assays","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis combined with binding assays and functional HIV suppression assay in a single study","pmids":["10364178"],"is_preprint":false},{"year":2008,"finding":"CCL3 signals through CCR5 to regulate intratumoral accumulation of macrophages, granulocytes, and fibroblasts; CCL3 stimulates macrophages to express MMP-9 and fibroblasts to express HGF, thereby promoting neovascularization and pulmonary metastasis.","method":"CCL3-/- and CCR5-/- gene-deficient mice, bone marrow chimeras, in vitro CCL3 stimulation, MMP-9 and HGF expression analysis","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models plus in vitro validation with specific cellular and molecular readouts","pmids":["18941229"],"is_preprint":false},{"year":2008,"finding":"ATP activates P2X7 receptors on microglia, causing dephosphorylation and nuclear translocation of the transcription factor NFAT, which drives CCL3 gene transcription and protein release; NFAT inhibition prevents CCL3 production.","method":"Pharmacological P2X7 agonist/antagonist studies, NFAT dephosphorylation assay, nuclear translocation imaging, NFAT inhibitor, siRNA not mentioned but inhibitor experiments in MG-5 cells and primary microglia","journal":"Journal of Neurochemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple pharmacological tools and NFAT translocation assay linking P2X7→NFAT→CCL3 axis","pmids":["19014371"],"is_preprint":false},{"year":2016,"finding":"Crystal structures of CCL3 oligomers in complex with glycosaminoglycans (GAGs) reveal that CCL3 forms high-molecular-weight oligomers, and GAG binding occurs via residues from two partially buried BBXB motifs that combine to form a GAG-binding groove in the CCL3 oligomer; an alternative CCL3 oligomer structure shows conformational changes in CCL3 N-termini that profoundly alter surface properties and dimer–dimer interactions to affect both GAG binding and oligomerization.","method":"X-ray crystallography, biophysical analyses (structural determination of GAG-bound CCL3 oligomers)","journal":"Proceedings of the National Academy of Sciences USA","confidence":"High","confidence_rationale":"Tier 1 — crystal structures with functional mutagenesis context, single rigorous structural study","pmids":["27091995"],"is_preprint":false},{"year":2004,"finding":"PGE2 inhibits CCL3 and CCL4 expression in dendritic cells via a signaling pathway: EP-2 receptor → cAMP → EPAC → PI3K → PKB → GSK-3, leading to increased DNA binding of the transcriptional repressor CDP (CCAAT displacement protein) to CCL3/CCL4 promoters; CDP knockdown by siRNA confirmed direct regulation of CCL3 transcription.","method":"Pharmacological pathway dissection, siRNA knockdown of CDP, EMSA/DNA-binding assays in dendritic cells","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple pathway inhibitors plus siRNA validation establishing direct transcriptional repression mechanism","pmids":["15498767"],"is_preprint":false},{"year":2003,"finding":"CCL3 is required for CD8+ T cell differentiation into effector cells during CNS viral infection: CCL3-/- mice have CD8+ T cells primed in lymph nodes that remain CD62L-high, CD25-low, and CCR7+, with reduced CCR5 and CXCR3 expression, impaired cytokine production, and reduced cytolytic activity, indicating CCL3 promotes the transition of primed CD8+ T cells to effector phenotype and their egress to infection sites.","method":"CCL3-/- mice, mouse hepatitis virus CNS infection, flow cytometry of T cell phenotypes, cytolytic activity assays","journal":"Journal of Virology","confidence":"High","confidence_rationale":"Tier 2 — clean KO with multiple orthogonal phenotypic readouts defining CCL3's role in T cell differentiation","pmids":["12634360"],"is_preprint":false},{"year":2006,"finding":"MIP-1α/CCL3 is a downstream transcriptional target of FGFR3 and RAS-MAPK signaling in multiple myeloma: FGFR3 inhibition (by kinase inhibitors or siRNA) suppresses CCL3 promoter activity, gene expression, and protein secretion, while ERK1 inhibition in RAS-mutant cells also downregulates CCL3, placing CCL3 downstream of the FGFR3→RAS→MAPK→ERK axis.","method":"FGFR3 kinase inhibitors, FGFR3-specific siRNA, FGF ligand stimulation, gene expression arrays, promoter reporter assays, ERK inhibition","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — multiple independent modulators of FGFR3 with promoter assay validation, defining signaling axis","pmids":["16849642"],"is_preprint":false},{"year":2011,"finding":"Tristetraprolin (TTP) binds CCL3 mRNA via conserved AU-rich elements and promotes its degradation; TTP-/- macrophages produce excess LPS-induced CCL3; double-knockout CCL3-/-TTP-/- mice show reduced inflammatory arthritis and attenuated atherosclerosis compared to TTP-/- mice, demonstrating TTP is a key post-transcriptional repressor of CCL3 in tissue inflammation.","method":"TTP mRNA-binding screen, CCL3-/-TTP-/- double knockout mice, arthritis and atherosclerosis models, plasma CCL3 measurement","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 2 — RNA-binding interaction established, double-KO genetic epistasis with multiple disease models","pmids":["21784977"],"is_preprint":false},{"year":2005,"finding":"Neutrophil-derived serine proteases (cathepsin G, elastase, proteinase 3) proteolytically cleave both LD78beta and LD78alpha isoforms of CCL3 at specific sites (Thr16-Ser17, Phe24-Ile25, Tyr28-Phe29, Thr31-Ser32), with cathepsin G preferentially cleaving Phe24-Ile25 and Tyr28-Phe29, and elastase/proteinase 3 cleaving Thr16-Ser17 and Thr31-Ser32; proteolysis of LD78beta abolishes its chemotactic activity.","method":"In vitro protease cleavage assays, mass spectrometry, peptide sequencing, serine protease inhibitors, chemotaxis assays; Papillon-Lefevre syndrome patient lysates as controls","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical reconstitution with MS-defined cleavage sites and functional chemotaxis readout","pmids":["15728180"],"is_preprint":false},{"year":2005,"finding":"CCL3 (MIP-1α) induces migration of GM-CSF-primed human neutrophils via CCR5, with ERK1/2 (but not ERK1 alone) and p38 MAPK as required intracellular signaling components; GM-CSF priming activates ERK-1 enabling CCR5-mediated CCL3 responsiveness in neutrophils.","method":"Chemotaxis assays, CCR5 antagonist TAK-779, ERK1/2 and p38 MAPK inhibitors, GM-CSF priming","journal":"Cellular Signalling","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibitors defining signaling pathway; single lab study","pmids":["15567066"],"is_preprint":false},{"year":2010,"finding":"CCL3 interacts specifically with CCR1 (not CCR5) to mediate radiation-induced pulmonary inflammation and fibrosis: CCL3-/- and CCR1-/- mice are protected from radiation-induced lung inflammation, fibrosis, and loss of lung function, while CCR5-/- mice are not protected; a small-molecule CCR1 inhibitor also prevented these conditions.","method":"CCL3-/-, CCR1-/-, CCR5-/- knockout mice, thoracic irradiation model, CCR1 pharmacological inhibitor, hydroxyproline assays, flow cytometry, lung function measurement","journal":"American Journal of Respiratory Cell and Molecular Biology","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models plus pharmacological validation, receptor specificity defined by differential KO phenotypes","pmids":["20870892"],"is_preprint":false},{"year":2012,"finding":"CCL3-mediated neutrophil extravasation requires leukocyte CCR1 and non-leukocyte CCR5; both G protein-receptor coupling and PI3Kγ signaling are essential for CCL3-induced neutrophil responses; β2 and α4 integrins and their counter-receptors ICAM-1 and VCAM-1 are required for CCL3-induced intravascular adherence and transmigration.","method":"In vivo microscopy (mouse cremaster muscle), Ccr1-/- and Ccr5-/- mice, cell-transfer techniques, PI3Kγ inhibitor, G protein inhibitor, integrin-blocking antibodies","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo intravital microscopy plus genetic and pharmacological dissection of receptor and signaling requirements","pmids":["22674804"],"is_preprint":false},{"year":2008,"finding":"CCL3 selectively mobilizes mature NK cells (mNK) from bone marrow by acting on CCR1-expressing mNK cells and by inhibiting CXCL12-mediated mNK cell retention in vitro; pNK and iNK cells expressing only CXCR4 do not respond directly to CCL3, establishing a stage-specific chemokine receptor regulation of NK cell bone marrow trafficking.","method":"In vivo CCL3 administration to C57BL/6 mice, CXCR4 antagonist AMD-3100, in vitro migration assays, flow cytometry of NK cell subsets","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo and in vitro experiments with stage-specific NK cell populations defining differential responsiveness","pmids":["18227348"],"is_preprint":false},{"year":2001,"finding":"CCL3 is required for activation of alveolar macrophage phagocytic function during Klebsiella pneumoniae pulmonary infection: CCL3-/- mice show an 800-fold higher lung bacterial burden, without defects in leukocyte recruitment, but with significantly lower phagocytic activity of CCL3-/- alveolar macrophages; this effect is mediated via CCR1 rather than CCR5.","method":"CCL3-/- and CCR5-/- mice, intratracheal K. pneumoniae infection, CFU counts, macrophage phagocytosis assay","journal":"Infection and Immunity","confidence":"High","confidence_rationale":"Tier 2 — multiple KO models with mechanistic dissection (phagocytosis assay) showing function beyond chemotaxis","pmids":["11553580"],"is_preprint":false},{"year":2011,"finding":"CCL3 inhibits osteoblast function via CCR1: CCL3 activates ERK and downregulates the osteogenic transcription factor osterix, suppressing mineralization and osteocalcin production in human bone marrow stromal cells; CCR1 inhibition restores ERK phosphorylation, osterix, and osteocalcin expression in CCL3-treated cells.","method":"Primary human bone marrow stromal cells, HS27A cells, ERK phosphorylation assays, osterix/osteocalcin expression, CCR1 small-molecule inhibitor, SCID-hu mouse model","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — in vitro mechanistic pathway (CCR1→ERK→osterix) with in vivo validation in SCID-hu mice","pmids":["21403648"],"is_preprint":false},{"year":2016,"finding":"CCL3 inhibits erythropoiesis of HSPCs via CCR1-p38 signaling: CCL3 increases p38 phosphorylation and downregulates the master erythroid transcription factor GATA1; CCR1 antagonist treatment partially recovers erythroid colony formation in the presence of CCL3 or leukemic bone marrow plasma.","method":"Colony-forming assays, cytokine array, CCR1 antagonist, p38 phosphorylation assay, GATA1 expression, CCL3 knockdown in AML mouse model","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — in vitro mechanistic dissection (CCR1→p38→GATA1) confirmed by CCL3 knockdown in vivo","pmids":["27109512"],"is_preprint":false},{"year":2020,"finding":"Elevated CCL3 in the bone marrow of multiple myeloma suppresses erythropoiesis of HSPCs via CCR1/p38 signaling and consequent suppression of GATA1 expression; CCR1 antagonist treatment recovers GATA1 expression and rescues erythropoiesis.","method":"CCR1 antagonist, p38 signaling analysis, GATA1 expression in patient-derived HSPCs, large clinical cohort correlation","journal":"Scientific Reports","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway consistent with and extending prior Leukemia paper; single lab","pmids":["33239656"],"is_preprint":false},{"year":2013,"finding":"CCL3 promotes hepatic stellate cell proliferation and migration in vitro, and CCL3-deficient mice show reduced stellate cell activation and liver immune cell infiltration in two fibrosis models, defining CCL3 as a direct mediator of liver fibrosis.","method":"CCL3-/- mice, carbon tetrachloride and methionine/choline-deficient diet fibrosis models, in vitro hepatic stellate cell proliferation and migration assays","journal":"PloS One","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro functional assay combined with two in vivo KO models","pmids":["23799074"],"is_preprint":false},{"year":2004,"finding":"CCL3 deficiency attenuates recruitment of CCR1-expressing CD4+ T cells to the liver during Con A-induced hepatitis and reduces hepatic IFN-γ production; dual CCR1/CCR5 antagonist (Met-RANTES) also reduces CD4+ T cell liver infiltration, demonstrating the CCL3-CCR1 pathway mediates CD4+ T cell-driven hepatic inflammation.","method":"CCL3-/- mice, Con A hepatitis model, flow cytometry, met-RANTES CCR1/CCR5 antagonist treatment","journal":"European Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — KO mice with pharmacological receptor antagonist validation","pmids":["15368307"],"is_preprint":false},{"year":2009,"finding":"IFN-γ is hierarchically required for CCL3-mediated neutrophil recruitment in vivo: CCL3 overexpression alone cannot elicit neutrophil recruitment in the absence of IFN-γ, and IFN-γ receptor-deleted mice show a 5-fold reduction in neutrophil recruitment despite CCR1 expression and ex vivo CCL3 responsiveness on their neutrophils.","method":"IFN-γ receptor-/- mice, CCL3 overexpression via viral vector, neutrophil ex vivo migration assays, pneumonia virus of mice infection model","journal":"BMC Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic dissection with ex vivo functional controls; single lab","pmids":["19298652"],"is_preprint":false},{"year":2012,"finding":"CCL3 and CCL2 are required for pelvic pain in experimental autoimmune prostatitis: anti-CCL3 neutralizing antibodies attenuate pain development; CCL3-deficient mice show resistance to maintenance of pelvic pain, while CCR5-/- mice do not, suggesting CCL3 acts through a receptor other than CCR5 for this pain phenotype.","method":"CCL3-/- and CCR5-/- mice, neutralizing antibodies, experimental autoimmune prostatitis model, mechanical pain assessment","journal":"American Journal of Physiology - Regulatory, Integrative and Comparative Physiology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple genetic and pharmacological approaches defining CCL3 role in pain maintenance","pmids":["22814670"],"is_preprint":false},{"year":2014,"finding":"CCL3 and P2X7 receptors in the spinal dorsal horn contribute to paclitaxel-induced mechanical allodynia: CCL3 and CCR5 are upregulated in the spinal dorsal horn of paclitaxel-treated rats; intrathecal CCL3-neutralizing antibody prevents and reverses allodynia; P2X7R antagonism also prevents allodynia, consistent with P2X7R-driven CCL3 release from spinal microglia.","method":"Rat paclitaxel neuropathy model, intrathecal CCL3-neutralizing antibody, P2X7R antagonist A438079, CCL3/CCR5 mRNA quantification, microglial counts","journal":"Molecular Pain","confidence":"Medium","confidence_rationale":"Tier 2 — neutralizing antibody and pharmacological receptor blockade in vivo with mechanistic correlation to P2X7→CCL3 axis established previously in vitro","pmids":["25127716"],"is_preprint":false},{"year":2006,"finding":"Central (i.c.v.) administration of CCL3 evokes an integrated febrile response with reduction in tail skin temperature and elevation of PGE2 in CSF; the fever is sensitive to ibuprofen and celecoxib but not to dexamethasone; indomethacin blocks the PGE2 rise but not the fever, indicating CCL3 can induce fever via PGE2-independent mechanisms as well.","method":"Intracerebroventricular CCL3 injection in rats, body temperature telemetry, tail skin temperature, CSF PGE2 ELISA, antipyretic drug treatments","journal":"Brain Research","confidence":"Medium","confidence_rationale":"Tier 2 — direct pharmacological manipulation in vivo with multiple readouts; single lab","pmids":["16836983"],"is_preprint":false},{"year":2013,"finding":"EBV oncoprotein LMP1 activates JNK signaling to upregulate CCL3 and CCL4 in B cells; autocrine CCL3 and CCL4 are required for LCL survival and growth, as their inhibition by shRNA or neutralizing antibodies suppresses proliferation and induces apoptosis.","method":"Cytokine antibody arrays, shRNA knockdown of CCL3/CCL4, neutralizing antibodies, LCL proliferation and apoptosis assays, JNK inhibitor","journal":"Journal of Virology","confidence":"Medium","confidence_rationale":"Tier 2 — shRNA and neutralizing antibody approaches with clear cellular phenotype; single lab","pmids":["23760235"],"is_preprint":false},{"year":2022,"finding":"Docetaxel (DTX) induces CCL3 in macrophages and cancer cells by relieving CREB-mediated inhibition of CCL3 via reactive oxygen species accumulation; CCL3 then promotes proinflammatory macrophage polarization via the CCL3-CCR5-p38/IRF5 signaling pathway, facilitating macrophage phagocytosis of breast cancer cells.","method":"CCL3-knockout transgenic mouse allograft model, macrophage depletion, RNA sequencing, in vitro co-culture phagocytosis assay, CREB inhibitor, pathway dissection","journal":"Journal for Immunotherapy of Cancer","confidence":"Medium","confidence_rationale":"Tier 2 — multiple in vivo and in vitro approaches defining ROS→CREB→CCL3→CCR5→p38/IRF5 mechanistic axis","pmids":["35613826"],"is_preprint":false},{"year":2020,"finding":"CCL3 signals through CCR5 to suppress MMP-9 expression in macrophages, thereby attenuating CaCl2-induced aortic aneurysm formation; CCL3-/- and CCR5-/- (but not CCR1-/-) mice show exaggerated aneurysm with augmented macrophage infiltration and MMP-9 expression; CCL3 treatment suppresses PMA-induced MMP-9 in macrophages in vitro.","method":"CCL3-/-, CCR5-/-, CCR1-/- mice, CaCl2 and angiotensin II aneurysm models, CCL3 immunoneutralization, in vitro macrophage MMP-9 assay, CCL3 treatment","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 — multiple receptor-specific KO lines plus in vivo neutralization and in vitro mechanistic validation defining CCL3-CCR5-MMP-9 axis","pmids":["33239616"],"is_preprint":false},{"year":2016,"finding":"LPS-induced CCL3 expression in microglia is regulated by p38 MAPK, ERK1/2, and NF-κB signaling pathways: pharmacological inhibition of each pathway reduces CCL3 protein levels and microglial accumulation in vivo; CCL3 neutralization attenuates microglial accumulation and upregulation of COX-2 and iNOS.","method":"In vivo LPS rat brain injury model, p38/ERK1/2/NF-κB inhibitors, anti-CCL3 neutralizing antibody, immunofluorescence, Western blot","journal":"Acta Neurobiologiae Experimentalis","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pharmacological pathway inhibitors with in vivo CCL3 neutralization; single lab","pmids":["28094821"],"is_preprint":false},{"year":2024,"finding":"H. pylori infection stimulates macrophages to secrete CCL3 via the JAK1-STAT1 signaling pathway (STAT1 identified as a direct transcription factor for CCL3 by dual-luciferase and chromatin immunoprecipitation assays); secreted CCL3 disrupts gastric epithelial tight junctions through P38 phosphorylation; neutralizing antibody or CCL3 receptor inhibition rescues tight junction integrity.","method":"RT-qPCR, Western blot, ELISA, dual-luciferase reporter assay, chromatin immunoprecipitation, transepithelial electrical resistance, P38 inhibitor, in vivo CCL3 injection in mice","journal":"Cell Communication and Signaling","confidence":"High","confidence_rationale":"Tier 1–2 — ChIP and luciferase assays establishing STAT1 as direct CCL3 transcription factor, with downstream P38 pathway and in vivo validation","pmids":["38730482"],"is_preprint":false},{"year":2023,"finding":"CCL3 promotes bone marrow stromal cell adipogenesis via a positive feedback loop: CCL3 activates STAT3 to induce C/EBPα expression, and C/EBPα in turn activates CCL3 promoter (facilitated by DNA hypomethylation); CCL3 simultaneously inhibits osteogenic differentiation by activating ERK, which upregulates DKK1 to block β-catenin activity; CCL3 neutralization in vivo rescues trabecular bone loss and bone marrow adiposity in aged mice.","method":"CCL3-/- mice, antibody-array serum profiling, in vitro BMSC differentiation assays, STAT3 inhibition, ERK inhibition, DKK1 assay, DNA methylation analysis, in vivo neutralizing antibody treatment","journal":"JCI Insight","confidence":"High","confidence_rationale":"Tier 2 — multiple signaling pathways mechanistically defined (STAT3→C/EBPα and ERK→DKK1→β-catenin) with in vivo genetic and antibody validation","pmids":["36378535"],"is_preprint":false},{"year":1992,"finding":"Recombinant CCL3 (LD78α and LD78β) stimulates osteoclast-like cell formation in rat bone marrow cultures in the presence of 1α,25-dihydroxyvitamin D3, and this activity is independent of prostaglandin synthesis, establishing a direct role for CCL3 in osteoclast differentiation.","method":"Rat bone marrow culture, recombinant LD78 protein, osteoclast-like cell formation assay, prostaglandin synthesis inhibitor","journal":"Bone and Mineral","confidence":"Medium","confidence_rationale":"Tier 3 — in vitro reconstitution with recombinant protein; single lab foundational study","pmids":["1472893"],"is_preprint":false},{"year":2017,"finding":"CCL3 inhibits ATP (BzATP)-induced release of IL-1β from monocytic cells via a CCR1-dependent mechanism involving calcium-independent phospholipase A2 (iPLA2), release of small mediators, and nicotinic acetylcholine receptor subunits α7 and α9 (triple-membrane-passing mechanism); siRNA knockdown of CCR1 or iPLA2 blunts the CCL3 inhibitory effect.","method":"U937 monocytic cells, siRNA knockdown of CCR1 and iPLA2, nicotinic receptor antagonists, IL-1β ELISA, BzATP P2X7 agonist stimulation","journal":"Mediators of Inflammation","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA and pharmacological dissection establishing CCR1→iPLA2→nicotinic receptor axis; single lab","pmids":["28757683"],"is_preprint":false},{"year":2024,"finding":"Abnormal mechanical stress on cartilage endplate chondrocytes activates Hippo signaling and Yap1 inhibition, driving CCL3 transcription (YAP1 overexpression directly blocks CCL3 promoter to suppress transcription); released CCL3 recruits osteoclasts and promotes their formation for cartilage endplate remodeling and intervertebral disc degeneration.","method":"Transcriptome sequencing, Yap1 knockout in cartilage, Hippo pathway activation/blockade, CCL3 ChIP-promoter analysis, osteoclast differentiation assays, AAV5-Yap1 rescue in vivo","journal":"Bone Research","confidence":"Medium","confidence_rationale":"Tier 2 — promoter ChIP and in vivo genetic rescue defining Hippo-YAP1→CCL3→osteoclast axis; single study","pmids":["38816384"],"is_preprint":false},{"year":2020,"finding":"miR-21 directly targets and downregulates CCL3 mRNA (validated by dual-luciferase reporter assay); CCL3 downregulation by miR-21 overexpression reduces NF-κB pathway activation (IKKα/β and p65 phosphorylation) and attenuates neonatal hypoxic-ischemic brain damage.","method":"Dual-luciferase reporter assay, in vivo gain/loss-of-function (miR-21 overexpression in HIBD rat model), Western blot, RT-qPCR","journal":"Apoptosis","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase assay establishes direct miRNA-CCL3 interaction; in vivo functional consequences demonstrated","pmids":["32306124"],"is_preprint":false},{"year":2013,"finding":"Leukocyte-derived CCL3 mediates neutrophil chemotaxis into atherosclerotic plaques: bone marrow chimeric LDLr-/- mice reconstituted with CCL3-/- bone marrow show 31% reduced lesion formation with significantly attenuated neutrophil adhesion and plaque presence, while plaque macrophage and collagen content are unchanged; CCL3-/- neutrophils show reduced CXCL1 responsiveness.","method":"Bone marrow chimeras (CCL3-/- into LDLr-/- mice), atherosclerosis model (Western diet), plaque histology, neutrophil turnover analysis, ex vivo chemotaxis","journal":"Arteriosclerosis, Thrombosis, and Vascular Biology","confidence":"Medium","confidence_rationale":"Tier 2 — bone marrow chimera establishes leukocyte-specific CCL3 as key source; cell-specific phenotypic analysis","pmids":["23288165"],"is_preprint":false}],"current_model":"CCL3 (MIP-1α/LD78) is a CC chemokine that signals through G protein-coupled receptors CCR1 and CCR5 to drive directed leukocyte chemotaxis, with receptor specificity determining context-dependent outcomes (e.g., CCR1 for radiation fibrosis and bacterial clearance, CCR5 for metastasis and aneurysm suppression); its N-terminal residues are critical for receptor binding affinity; it forms oligomers that bind glycosaminoglycans via a distinct groove; its mRNA is post-transcriptionally destabilized by tristetraprolin; its transcription is driven downstream of FGFR3-RAS-MAPK/ERK, NF-κB, p38, JAK1-STAT1, and NFAT (via P2X7 receptor), and repressed by PGE2 through an EP2-cAMP-EPAC-PI3K-PKB-GSK3-CDP axis; secreted CCL3 activates macrophages to produce MMP-9, promotes osteoclast differentiation, inhibits osteoblast function via CCR1-ERK-osterix, suppresses erythropoiesis via CCR1-p38-GATA1, and promotes adipogenesis of bone marrow stromal cells via STAT3-C/EBPα while inhibiting osteogenesis via ERK-DKK1-β-catenin; neutrophil-derived serine proteases proteolytically inactivate CCL3 at defined sites to limit inflammation."},"narrative":{"teleology":[{"year":1992,"claim":"Before CCL3's in vivo role was defined, its capacity to stimulate osteoclast-like cell formation in vitro established it as more than a simple chemoattractant, linking it to bone remodeling.","evidence":"Recombinant LD78 protein added to rat bone marrow cultures stimulated osteoclast formation independent of prostaglandin synthesis","pmids":["1472893"],"confidence":"Medium","gaps":["Single in vitro system; in vivo relevance to osteoclastogenesis not demonstrated","Receptor mediating osteoclast effect unidentified","Mechanism of CCL3-driven osteoclast differentiation undefined"]},{"year":1993,"claim":"Identification of CCR1 (HM145) as a functional GPCR for CCL3 established that CCL3 signals through a specific receptor to inhibit cAMP and mobilize calcium, providing the first receptor-coupling framework.","evidence":"Stable transfectants expressing cloned CCR1 showed CCL3-induced cAMP decrease and calcium influx","pmids":["7505609"],"confidence":"High","gaps":["CCR5 not yet identified as second CCL3 receptor","Downstream signaling beyond cAMP/calcium not mapped"]},{"year":1995,"claim":"Genetic ablation of CCL3 demonstrated it is an essential mediator of virus-induced inflammatory cell recruitment in vivo, establishing its non-redundant role in host defense.","evidence":"CCL3-knockout mice were resistant to Coxsackievirus-induced myocarditis and showed reduced pneumonitis with delayed influenza viral clearance","pmids":["7667639"],"confidence":"High","gaps":["Receptor(s) mediating the in vivo phenotype not defined","Whether CCL3 acts beyond chemotaxis (e.g., on effector cell function) was unknown"]},{"year":1999,"claim":"Site-directed mutagenesis of the N-terminal proline-2 residue revealed that a single amino acid determines receptor-binding selectivity between CCR5 and D6 and profoundly affects HIV-1 suppressive potency, establishing the N-terminus as the critical receptor-engagement determinant.","evidence":"LD78β (Pro2) showed ~6-fold enhanced CCR5 binding and ~15–20-fold enhanced D6 binding versus LD78α, with markedly higher HIV suppression","pmids":["10364178"],"confidence":"High","gaps":["Structural basis for Pro2-enhanced binding not resolved","In vivo relevance of LD78β isoform preference not tested"]},{"year":2001,"claim":"The finding that CCL3 activates macrophage phagocytosis during bacterial infection—independent of leukocyte recruitment—established a non-chemotactic effector function for CCL3, mediated specifically through CCR1.","evidence":"CCL3-/- mice had 800-fold higher lung bacterial burden without recruitment defects; CCL3-/- alveolar macrophages had reduced phagocytic activity; CCR5-/- mice were unaffected","pmids":["11553580"],"confidence":"High","gaps":["Signaling pathway linking CCR1 to phagocytic activation undefined","Whether CCL3 directly enhances killing versus uptake unclear"]},{"year":2003,"claim":"CCL3 was shown to be required not only for chemotaxis but also for the differentiation of primed CD8+ T cells into functional effectors during CNS viral infection, expanding its role to adaptive immune programming.","evidence":"CCL3-/- mice had CD8+ T cells stuck in a CD62Lhi/CD25lo/CCR7+ naive-like state with impaired cytokine production and cytolytic activity","pmids":["12634360"],"confidence":"High","gaps":["Whether CCL3 acts directly on T cells or indirectly via APCs not resolved","Receptor specificity for T cell differentiation effect unknown"]},{"year":2004,"claim":"Dissection of the PGE2 repression pathway revealed a complete signaling cascade (EP2→cAMP→EPAC→PI3K→PKB→GSK3→CDP) that directly represses CCL3 transcription, defining the first negative transcriptional regulatory axis for CCL3.","evidence":"Pharmacological pathway dissection and CDP siRNA knockdown in dendritic cells with EMSA confirmation of CDP binding to CCL3 promoter","pmids":["15498767"],"confidence":"High","gaps":["Whether other transcriptional repressors cooperate with CDP unknown","Relevance to non-DC cell types not tested"]},{"year":2005,"claim":"Biochemical identification of specific proteolytic cleavage sites in CCL3 by neutrophil serine proteases defined a post-secretory inactivation mechanism that limits CCL3-driven inflammation at sites of neutrophil degranulation.","evidence":"In vitro cleavage by cathepsin G, elastase, and proteinase 3 mapped by mass spectrometry; cleavage abolished chemotactic activity","pmids":["15728180"],"confidence":"High","gaps":["In vivo significance of proteolytic inactivation not directly tested","Whether truncated fragments have residual or altered bioactivity unknown"]},{"year":2006,"claim":"Placing CCL3 downstream of FGFR3-RAS-MAPK/ERK signaling in myeloma cells identified CCL3 as a transcriptional effector of oncogenic kinase pathways, explaining elevated CCL3 in FGFR3-driven malignancy.","evidence":"FGFR3 kinase inhibitors, FGFR3 siRNA, and ERK inhibition all suppressed CCL3 promoter activity and protein secretion in myeloma cells","pmids":["16849642"],"confidence":"High","gaps":["Specific transcription factor downstream of ERK that binds CCL3 promoter not identified","Whether RAS-mutant and FGFR3-driven regulation are additive unknown"]},{"year":2008,"claim":"Multiple 2008 studies resolved receptor-specific functions: CCL3 acts through CCR5 to promote metastasis-associated macrophage MMP-9 and fibroblast HGF production, through CCR1 to mobilize mature NK cells from bone marrow, and through P2X7-NFAT to drive CCL3 transcription in microglia.","evidence":"CCL3-/- and CCR5-/- bone marrow chimeras for metastasis; CCR1-expressing mNK migration assays; P2X7 agonist/NFAT inhibitor experiments in microglia","pmids":["18941229","18227348","19014371"],"confidence":"High","gaps":["Whether CCR1 and CCR5 activate distinct signaling cascades in the same cell type not compared","NFAT isoform specificity for CCL3 transcription not determined"]},{"year":2010,"claim":"Receptor-specificity was further refined when CCR1 (but not CCR5) was identified as the obligate receptor for radiation-induced pulmonary fibrosis, demonstrating that context-specific pathology depends on which receptor CCL3 engages.","evidence":"CCL3-/- and CCR1-/- mice were protected from radiation fibrosis while CCR5-/- mice were not; CCR1 small-molecule inhibitor also prevented fibrosis","pmids":["20870892"],"confidence":"High","gaps":["Cell type expressing CCR1 that drives fibrosis not definitively identified","Whether CCL3 is the sole CCR1 ligand responsible not excluded"]},{"year":2011,"claim":"Two parallel advances defined CCL3's bone-remodeling and post-transcriptional control: CCL3 inhibits osteoblast differentiation via CCR1→ERK→osterix suppression, and tristetraprolin destabilizes CCL3 mRNA to limit inflammation, as shown by double-knockout genetic epistasis.","evidence":"CCR1 inhibitor restored osterix and osteocalcin in CCL3-treated stromal cells; TTP-/-/CCL3-/- double-KO mice had reduced arthritis and atherosclerosis versus TTP-/-","pmids":["21403648","21784977"],"confidence":"High","gaps":["Whether TTP regulation of CCL3 is tissue-specific unknown","Additional post-transcriptional regulators beyond TTP not surveyed"]},{"year":2012,"claim":"Intravital microscopy dissected the cellular choreography of CCL3-induced neutrophil extravasation: leukocyte CCR1 and non-leukocyte CCR5 cooperate, with PI3Kγ and β2/α4 integrins required, establishing the multi-cellular receptor cooperation model.","evidence":"Cremaster intravital microscopy with CCR1-/- and CCR5-/- chimeras, PI3Kγ inhibitor, and integrin-blocking antibodies","pmids":["22674804"],"confidence":"High","gaps":["Non-leukocyte cell type expressing CCR5 (endothelial vs. perivascular) not resolved","Whether this cooperative model extends beyond cremaster tissue unknown"]},{"year":2016,"claim":"Crystal structures of CCL3 oligomers with glycosaminoglycans revealed that oligomerization creates a composite GAG-binding groove from partially buried BBXB motifs, and N-terminal conformational changes modulate dimer–dimer interactions, providing the structural basis for GAG-dependent chemokine presentation.","evidence":"X-ray crystallography of GAG-bound CCL3 oligomers with biophysical analyses","pmids":["27091995"],"confidence":"High","gaps":["Functional impact of specific GAG-binding residue mutations on in vivo chemotaxis not tested","Whether different GAG types preferentially bind distinct CCL3 oligomeric states unknown"]},{"year":2016,"claim":"CCL3 was found to suppress erythropoiesis via CCR1→p38→GATA1 downregulation, defining a direct mechanism for anemia in leukemic bone marrow microenvironments.","evidence":"Colony-forming assays with CCR1 antagonist and p38 analysis; CCL3 knockdown rescued erythropoiesis in AML mouse model","pmids":["27109512"],"confidence":"High","gaps":["Whether CCL3 acts directly on erythroid progenitors versus through niche cells not fully resolved","Interaction between p38-GATA1 and other erythroid regulators not explored"]},{"year":2020,"claim":"CCL3 signaling through CCR5 was shown to suppress MMP-9 in macrophages and protect against aneurysm, revealing a previously unrecognized anti-inflammatory/tissue-protective function through CCR5, contrasting with CCR5's pro-metastatic role in other contexts.","evidence":"CCL3-/- and CCR5-/- (but not CCR1-/-) mice had exaggerated aneurysm; CCL3 treatment suppressed PMA-induced MMP-9 in vitro","pmids":["33239616"],"confidence":"High","gaps":["Downstream signaling mechanism by which CCR5 suppresses MMP-9 transcription not identified","Whether this protective role extends to other vascular pathologies unknown"]},{"year":2023,"claim":"A dual signaling mechanism was established for CCL3 in bone marrow stromal cells: STAT3→C/EBPα promotes adipogenesis (with a C/EBPα→CCL3 promoter positive feedback loop) while ERK→DKK1 inhibits β-catenin-dependent osteogenesis, providing a unified framework for CCL3's role in age-related bone loss.","evidence":"CCL3-/- mice, in vitro BMSC differentiation with STAT3/ERK inhibitors, DKK1 assay, DNA methylation analysis, in vivo neutralizing antibody rescue of trabecular bone","pmids":["36378535"],"confidence":"High","gaps":["Whether this mechanism operates in myeloma bone disease in addition to aging not tested","Epigenetic feedback loop (DNA hypomethylation) mechanism not fully defined"]},{"year":2024,"claim":"STAT1 was identified as a direct transcription factor for CCL3 downstream of JAK1 in H. pylori-stimulated macrophages, and secreted CCL3 was shown to disrupt epithelial tight junctions via p38, extending CCL3's functional repertoire to barrier disruption.","evidence":"ChIP and dual-luciferase reporter confirmed STAT1 binding to CCL3 promoter; transepithelial resistance measurements with p38 inhibitor and in vivo CCL3 injection","pmids":["38730482"],"confidence":"High","gaps":["Whether STAT1 cooperates with NF-κB at the CCL3 promoter in this context not tested","Tight junction targets downstream of p38 not identified"]},{"year":null,"claim":"Outstanding questions include how CCR1 and CCR5 activate divergent (sometimes opposing) downstream programs in the same cell type, the structural basis for oligomer-dependent receptor activation in vivo, and whether proteolytic processing generates bioactive CCL3 fragments with distinct receptor selectivity.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of CCL3-CCR1 or CCL3-CCR5 signaling complex exists","In vivo relevance of neutrophil protease-mediated CCL3 inactivation not demonstrated","Mechanism by which CCL3 promotes CD8+ T cell effector differentiation (direct vs. indirect) unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[1,2,3,11,12,13,14,16,17,27]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[16,17,27,30]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,3,5,10,14,15,29]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,7,13,15,20,21,35]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,3,11,12,16,17,26,27,29,30]}],"complexes":[],"partners":["CCR1","CCR5","TTP","STAT1","NFAT"],"other_free_text":[]},"mechanistic_narrative":"CCL3 (MIP-1α) is a CC chemokine that orchestrates innate and adaptive immune responses by driving leukocyte chemotaxis, activation, and tissue inflammation through its receptors CCR1 and CCR5, while also regulating bone homeostasis and hematopoiesis. CCL3 signals through CCR1 to activate macrophage phagocytosis, mediate radiation-induced pulmonary fibrosis, suppress erythropoiesis via p38-GATA1, and inhibit osteoblast differentiation via ERK-osterix, whereas CCR5-dependent signaling promotes metastasis-associated macrophage MMP-9 production, proinflammatory macrophage polarization via p38/IRF5, and suppression of aortic aneurysm through MMP-9 downregulation [PMID:18941229, PMID:20870892, PMID:27109512, PMID:21403648, PMID:33239616]. CCL3 forms high-molecular-weight oligomers that bind glycosaminoglycans via a composite groove formed by partially buried BBXB motifs, and its N-terminal residues critically determine receptor affinity and HIV-suppressive potency [PMID:27091995, PMID:10364178]. CCL3 transcription is driven by FGFR3-RAS-MAPK/ERK, NF-κB, p38, JAK1-STAT1, and NFAT pathways and repressed by PGE2 through an EP2-cAMP-EPAC-PI3K-PKB-GSK3-CDP axis; its mRNA is post-transcriptionally destabilized by tristetraprolin and targeted by miR-21, while neutrophil serine proteases proteolytically inactivate secreted CCL3 at defined sites to limit inflammation [PMID:16849642, PMID:15498767, PMID:19014371, PMID:21784977, PMID:15728180, PMID:38730482]."},"prefetch_data":{"uniprot":{"accession":"P10147","full_name":"C-C motif chemokine 3","aliases":["G0/G1 switch regulatory protein 19-1","Macrophage inflammatory protein 1-alpha","MIP-1-alpha","PAT 464.1","SIS-beta","Small-inducible cytokine A3","Tonsillar lymphocyte LD78 alpha protein"],"length_aa":92,"mass_kda":10.1,"function":"Monokine with inflammatory and chemokinetic properties. Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P10147/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL3","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1165,"dependency_fraction":0.0017167381974248926},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL3","total_profiled":1310},"omim":[{"mim_id":"614061","title":"OLFACTOMEDIN 4; OLFM4","url":"https://www.omim.org/entry/614061"},{"mim_id":"613665","title":"ATYPICAL CHEMOKINE RECEPTOR 1; ACKR1","url":"https://www.omim.org/entry/613665"},{"mim_id":"610369","title":"HEAT-SHOCK 70-KD PROTEIN 14; HSPA14","url":"https://www.omim.org/entry/610369"},{"mim_id":"609467","title":"CHEMOKINE, CC MOTIF, LIGAND 3, PSEUDOGENE 1; CCL3P1","url":"https://www.omim.org/entry/609467"},{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":72.7},{"tissue":"lung","ntpm":35.3},{"tissue":"lymphoid tissue","ntpm":48.7}],"url":"https://www.proteinatlas.org/search/CCL3"},"hgnc":{"alias_symbol":["G0S19-1","LD78ALPHA","MIP-1-alpha","LD78","SCI"],"prev_symbol":["SCYA3"]},"alphafold":{"accession":"P10147","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P10147","model_url":"https://alphafold.ebi.ac.uk/files/AF-P10147-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P10147-F1-predicted_aligned_error_v6.png","plddt_mean":88.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL3","jax_strain_url":"https://www.jax.org/strain/search?query=CCL3"},"sequence":{"accession":"P10147","fasta_url":"https://rest.uniprot.org/uniprotkb/P10147.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P10147/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P10147"}},"corpus_meta":[{"pmid":"7667639","id":"PMC_7667639","title":"Requirement of MIP-1 alpha for an inflammatory response to viral infection.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7667639","citation_count":514,"is_preprint":false},{"pmid":"8558069","id":"PMC_8558069","title":"The role of MIP-1 alpha in inflammation and hematopoiesis.","date":"1996","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/8558069","citation_count":172,"is_preprint":false},{"pmid":"7505609","id":"PMC_7505609","title":"Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors.","date":"1993","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7505609","citation_count":142,"is_preprint":false},{"pmid":"18941229","id":"PMC_18941229","title":"CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18941229","citation_count":138,"is_preprint":false},{"pmid":"21403648","id":"PMC_21403648","title":"A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.","date":"2011","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/21403648","citation_count":128,"is_preprint":false},{"pmid":"28965431","id":"PMC_28965431","title":"Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3.","date":"2017","source":"Expert review of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28965431","citation_count":121,"is_preprint":false},{"pmid":"1694014","id":"PMC_1694014","title":"Structures of human genes coding for cytokine LD78 and their expression.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1694014","citation_count":117,"is_preprint":false},{"pmid":"19014371","id":"PMC_19014371","title":"Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT.","date":"2008","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19014371","citation_count":110,"is_preprint":false},{"pmid":"10364178","id":"PMC_10364178","title":"LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10364178","citation_count":110,"is_preprint":false},{"pmid":"21115978","id":"PMC_21115978","title":"CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21115978","citation_count":108,"is_preprint":false},{"pmid":"30419802","id":"PMC_30419802","title":"The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer.","date":"2018","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30419802","citation_count":104,"is_preprint":false},{"pmid":"12634360","id":"PMC_12634360","title":"CC chemokine ligand 3 (CCL3) regulates CD8(+)-T-cell effector function and migration following viral infection.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12634360","citation_count":100,"is_preprint":false},{"pmid":"18227348","id":"PMC_18227348","title":"CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18227348","citation_count":96,"is_preprint":false},{"pmid":"30551457","id":"PMC_30551457","title":"Inhibition of TREM1 reduces inflammation and oxidative stress after spinal cord injury (SCI) associated with HO-1 expressions.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30551457","citation_count":92,"is_preprint":false},{"pmid":"26133170","id":"PMC_26133170","title":"Increased CCL2, CCL3, CCL5, and IL-1β cytokine concentration in piriform cortex, hippocampus, and neocortex after pilocarpine-induced seizures.","date":"2015","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/26133170","citation_count":90,"is_preprint":false},{"pmid":"17618978","id":"PMC_17618978","title":"Sodium channel expression and the molecular pathophysiology of pain after SCI.","date":"2007","source":"Progress in brain research","url":"https://pubmed.ncbi.nlm.nih.gov/17618978","citation_count":86,"is_preprint":false},{"pmid":"32060842","id":"PMC_32060842","title":"CCL3 Signaling in the Tumor Microenvironment.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32060842","citation_count":83,"is_preprint":false},{"pmid":"25017887","id":"PMC_25017887","title":"Neuroinflammatory contributions to pain after SCI: roles for central glial mechanisms and nociceptor-mediated host defense.","date":"2014","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25017887","citation_count":83,"is_preprint":false},{"pmid":"16284949","id":"PMC_16284949","title":"Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16284949","citation_count":83,"is_preprint":false},{"pmid":"17621255","id":"PMC_17621255","title":"TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome.","date":"2008","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/17621255","citation_count":76,"is_preprint":false},{"pmid":"15498767","id":"PMC_15498767","title":"A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15498767","citation_count":70,"is_preprint":false},{"pmid":"23288165","id":"PMC_23288165","title":"Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation.","date":"2013","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23288165","citation_count":67,"is_preprint":false},{"pmid":"12651617","id":"PMC_12651617","title":"Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas.","date":"2003","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12651617","citation_count":67,"is_preprint":false},{"pmid":"21360237","id":"PMC_21360237","title":"Targeting microvasculature for neuroprotection after SCI.","date":"2011","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21360237","citation_count":66,"is_preprint":false},{"pmid":"11553580","id":"PMC_11553580","title":"Macrophage inflammatory protein 1alpha/CCL3 is required for clearance of an acute Klebsiella pneumoniae pulmonary infection.","date":"2001","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11553580","citation_count":66,"is_preprint":false},{"pmid":"35613826","id":"PMC_35613826","title":"Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35613826","citation_count":65,"is_preprint":false},{"pmid":"27091995","id":"PMC_27091995","title":"Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27091995","citation_count":65,"is_preprint":false},{"pmid":"15368307","id":"PMC_15368307","title":"CCL3/MIP-1alpha is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4(+) T cells to the liver.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15368307","citation_count":65,"is_preprint":false},{"pmid":"22814670","id":"PMC_22814670","title":"CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis.","date":"2012","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22814670","citation_count":65,"is_preprint":false},{"pmid":"27308309","id":"PMC_27308309","title":"Role of macrophage inflammatory protein (MIP)-1α/CCL3 in leukemogenesis.","date":"2014","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27308309","citation_count":63,"is_preprint":false},{"pmid":"23799074","id":"PMC_23799074","title":"The chemokine CCL3 promotes experimental liver fibrosis in mice.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23799074","citation_count":61,"is_preprint":false},{"pmid":"25127716","id":"PMC_25127716","title":"Involvement of the chemokine CCL3 and the purinoceptor P2X7 in the spinal cord in paclitaxel-induced mechanical allodynia.","date":"2014","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/25127716","citation_count":61,"is_preprint":false},{"pmid":"16849642","id":"PMC_16849642","title":"MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16849642","citation_count":59,"is_preprint":false},{"pmid":"25183374","id":"PMC_25183374","title":"Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum.","date":"2014","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/25183374","citation_count":54,"is_preprint":false},{"pmid":"20870892","id":"PMC_20870892","title":"The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis.","date":"2010","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20870892","citation_count":54,"is_preprint":false},{"pmid":"21784977","id":"PMC_21784977","title":"Zinc finger protein tristetraprolin interacts with CCL3 mRNA and regulates tissue inflammation.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21784977","citation_count":54,"is_preprint":false},{"pmid":"35691078","id":"PMC_35691078","title":"The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis.","date":"2022","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35691078","citation_count":53,"is_preprint":false},{"pmid":"22674804","id":"PMC_22674804","title":"C-C motif chemokine CCL3 and canonical neutrophil attractants promote neutrophil extravasation through common and distinct mechanisms.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22674804","citation_count":51,"is_preprint":false},{"pmid":"2687328","id":"PMC_2687328","title":"Synthesis of a novel cytokine and its gene (LD78) expressions in hematopoietic fresh tumor cells and cell lines.","date":"1989","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/2687328","citation_count":51,"is_preprint":false},{"pmid":"27522478","id":"PMC_27522478","title":"Role of interleukin-4, the chemokine CCL3 and its receptor CCR5 in neuropathic pain.","date":"2016","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27522478","citation_count":50,"is_preprint":false},{"pmid":"22691208","id":"PMC_22691208","title":"CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment.","date":"2012","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/22691208","citation_count":50,"is_preprint":false},{"pmid":"15728180","id":"PMC_15728180","title":"Proteolysis of macrophage inflammatory protein-1alpha isoforms LD78beta and LD78alpha by neutrophil-derived serine proteases.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15728180","citation_count":49,"is_preprint":false},{"pmid":"15567066","id":"PMC_15567066","title":"CCL3 (MIP-1alpha) induces in vitro migration of GM-CSF-primed human neutrophils via CCR5-dependent activation of ERK 1/2.","date":"2005","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/15567066","citation_count":47,"is_preprint":false},{"pmid":"15634233","id":"PMC_15634233","title":"Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies.","date":"2005","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/15634233","citation_count":45,"is_preprint":false},{"pmid":"33239616","id":"PMC_33239616","title":"Prevention of CaCl2-induced aortic inflammation and subsequent aneurysm formation by the CCL3-CCR5 axis.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33239616","citation_count":44,"is_preprint":false},{"pmid":"17914560","id":"PMC_17914560","title":"Dual role of CCL3/CCR1 in oral squamous cell carcinoma: implications in tumor metastasis and local host defense.","date":"2007","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/17914560","citation_count":44,"is_preprint":false},{"pmid":"19298652","id":"PMC_19298652","title":"Interferon-gamma coordinates CCL3-mediated neutrophil recruitment in vivo.","date":"2009","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19298652","citation_count":44,"is_preprint":false},{"pmid":"17475893","id":"PMC_17475893","title":"The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17475893","citation_count":43,"is_preprint":false},{"pmid":"28881626","id":"PMC_28881626","title":"Relevance of CCL3/CCR5 axis in oral carcinogenesis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28881626","citation_count":41,"is_preprint":false},{"pmid":"11553568","id":"PMC_11553568","title":"Regulatory effects of macrophage inflammatory protein 1alpha/CCL3 on the development of immunity to Cryptococcus neoformans depend on expression of early inflammatory cytokines.","date":"2001","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11553568","citation_count":41,"is_preprint":false},{"pmid":"30279500","id":"PMC_30279500","title":"The Chemokine CCL3 Regulates Myeloid Differentiation and Hematopoietic Stem Cell Numbers.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30279500","citation_count":39,"is_preprint":false},{"pmid":"33239656","id":"PMC_33239656","title":"Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33239656","citation_count":39,"is_preprint":false},{"pmid":"20524925","id":"PMC_20524925","title":"Cardiovascular disease, SCI and exercise: unique risks and focused countermeasures.","date":"2010","source":"Disability and rehabilitation","url":"https://pubmed.ncbi.nlm.nih.gov/20524925","citation_count":37,"is_preprint":false},{"pmid":"27639636","id":"PMC_27639636","title":"Acute spinal cord injury (SCI) transforms how GABA affects nociceptive sensitization.","date":"2016","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27639636","citation_count":37,"is_preprint":false},{"pmid":"9702779","id":"PMC_9702779","title":"Directed selection of MIP-1 alpha neutralizing CCR5 antibodies from a phage display human antibody library.","date":"1998","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/9702779","citation_count":36,"is_preprint":false},{"pmid":"10049593","id":"PMC_10049593","title":"Chemokine PARC gene (SCYA18) generated by fusion of two MIP-1alpha/LD78alpha-like genes.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10049593","citation_count":35,"is_preprint":false},{"pmid":"38816384","id":"PMC_38816384","title":"Lumbar instability remodels cartilage endplate to induce intervertebral disc degeneration by recruiting osteoclasts via Hippo-CCL3 signaling.","date":"2024","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/38816384","citation_count":34,"is_preprint":false},{"pmid":"27109512","id":"PMC_27109512","title":"Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1α/CCL3.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/27109512","citation_count":34,"is_preprint":false},{"pmid":"28757683","id":"PMC_28757683","title":"Chemokines (CCL3, CCL4, and CCL5) Inhibit ATP-Induced Release of IL-1β by Monocytic Cells.","date":"2017","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/28757683","citation_count":34,"is_preprint":false},{"pmid":"31494219","id":"PMC_31494219","title":"The effects of CCL3, CCL4, CCL19 and CCL21 as molecular adjuvants on the immune response to VAA DNA vaccine in flounder (Paralichthys olivaceus).","date":"2019","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31494219","citation_count":33,"is_preprint":false},{"pmid":"27818188","id":"PMC_27818188","title":"Complete spinal cord injury (SCI) transforms how brain derived neurotrophic factor (BDNF) affects nociceptive sensitization.","date":"2016","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27818188","citation_count":32,"is_preprint":false},{"pmid":"12144807","id":"PMC_12144807","title":"Crucial role of CCL3/MIP-1alpha in the recurrence of autoimmune anterior uveitis induced with myelin basic protein in Lewis rats.","date":"2002","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/12144807","citation_count":32,"is_preprint":false},{"pmid":"32306124","id":"PMC_32306124","title":"miR-21 protects neonatal rats from hypoxic-ischemic brain damage by targeting CCL3.","date":"2020","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/32306124","citation_count":30,"is_preprint":false},{"pmid":"25060177","id":"PMC_25060177","title":"Serum CCL2 and CCL3 as potential biomarkers for the diagnosis of oral squamous cell carcinoma.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25060177","citation_count":28,"is_preprint":false},{"pmid":"31898342","id":"PMC_31898342","title":"Transcription factor RUNX3 promotes CD8+ T cell recruitment by CCL3 and CCL20 in lung adenocarcinoma immune microenvironment.","date":"2020","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31898342","citation_count":28,"is_preprint":false},{"pmid":"15043189","id":"PMC_15043189","title":"MIP-1 alpha and myeloma bone disease.","date":"2004","source":"Cancer treatment and research","url":"https://pubmed.ncbi.nlm.nih.gov/15043189","citation_count":28,"is_preprint":false},{"pmid":"29511496","id":"PMC_29511496","title":"MiR-103 alleviates autophagy and apoptosis by regulating SOX2 in LPS-injured PC12 cells and SCI rats.","date":"2018","source":"Iranian journal of basic medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29511496","citation_count":28,"is_preprint":false},{"pmid":"23760235","id":"PMC_23760235","title":"Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/23760235","citation_count":27,"is_preprint":false},{"pmid":"37227653","id":"PMC_37227653","title":"The Role of CCL3 in the Pathogenesis of Rheumatoid Arthritis.","date":"2023","source":"Rheumatology and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37227653","citation_count":26,"is_preprint":false},{"pmid":"31493490","id":"PMC_31493490","title":"Mechanisms of Below-Level Pain Following Spinal Cord Injury (SCI).","date":"2019","source":"The journal of pain","url":"https://pubmed.ncbi.nlm.nih.gov/31493490","citation_count":26,"is_preprint":false},{"pmid":"33535036","id":"PMC_33535036","title":"Systematic analysis of purified astrocytes after SCI unveils Zeb2os function during astrogliosis.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33535036","citation_count":26,"is_preprint":false},{"pmid":"16836983","id":"PMC_16836983","title":"CCL3/macrophage inflammatory protein-1alpha induces fever and increases prostaglandin E2 in cerebrospinal fluid of rats: effect of antipyretic drugs.","date":"2006","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/16836983","citation_count":25,"is_preprint":false},{"pmid":"33772780","id":"PMC_33772780","title":"Driving T cells to human atherosclerotic plaques: CCL3/CCR5 and CX3CL1/CX3CR1 migration axes.","date":"2021","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33772780","citation_count":24,"is_preprint":false},{"pmid":"35403834","id":"PMC_35403834","title":"A Selective β-Catenin-Metadherin/CEACAM1-CCL3 Axis Mediates Metastatic Heterogeneity upon Tumor-Macrophage Interaction.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/35403834","citation_count":23,"is_preprint":false},{"pmid":"27830143","id":"PMC_27830143","title":"MicroRNA-146a Contributes to SCI Recovery via Regulating TRAF6 and IRAK1 Expression.","date":"2016","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/27830143","citation_count":23,"is_preprint":false},{"pmid":"20452453","id":"PMC_20452453","title":"Role of CCL3/MIP-1alpha and CCL5/RANTES during acute Trypanosoma cruzi infection in rats.","date":"2010","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/20452453","citation_count":23,"is_preprint":false},{"pmid":"24809505","id":"PMC_24809505","title":"Chemokine expression of CCL2, CCL3, CCL5 and CXCL10 during early inflammatory tendon healing precedes nerve regeneration: an immunohistochemical study in the rat.","date":"2014","source":"Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA","url":"https://pubmed.ncbi.nlm.nih.gov/24809505","citation_count":23,"is_preprint":false},{"pmid":"31316152","id":"PMC_31316152","title":"RNA sequencing analysis revealed the induction of CCL3 expression in human intracranial aneurysms.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31316152","citation_count":22,"is_preprint":false},{"pmid":"28094821","id":"PMC_28094821","title":"Upregulation of CCL3/MIP-1alpha regulated by MAPKs and NF-kappaB mediates microglial inflammatory response in LPS-induced brain injury.","date":"2016","source":"Acta neurobiologiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/28094821","citation_count":22,"is_preprint":false},{"pmid":"35205100","id":"PMC_35205100","title":"Role of Descending Serotonergic Fibers in the Development of Pathophysiology after Spinal Cord Injury (SCI): Contribution to Chronic Pain, Spasticity, and Autonomic Dysreflexia.","date":"2022","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35205100","citation_count":22,"is_preprint":false},{"pmid":"10471782","id":"PMC_10471782","title":"Enhanced anti-HIV-1 activity of CC-chemokine LD78beta, a non-allelic variant of MIP-1alpha/LD78alpha.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10471782","citation_count":21,"is_preprint":false},{"pmid":"33981848","id":"PMC_33981848","title":"Recombinant Bacteroides fragilis enterotoxin-1 (rBFT-1) promotes proliferation of colorectal cancer via CCL3-related molecular pathways.","date":"2021","source":"Open life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33981848","citation_count":21,"is_preprint":false},{"pmid":"7537510","id":"PMC_7537510","title":"Identification of MIP-1 alpha/LD78 as a monocyte chemoattractant released by the HTLV-I-transformed cell line MT4.","date":"1995","source":"AIDS research and human retroviruses","url":"https://pubmed.ncbi.nlm.nih.gov/7537510","citation_count":21,"is_preprint":false},{"pmid":"24331998","id":"PMC_24331998","title":"In vitro regulation of CCL3 and CXCL12 by bacterial by-products is dependent on site of origin of human oral fibroblasts.","date":"2013","source":"Journal of endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/24331998","citation_count":21,"is_preprint":false},{"pmid":"8453306","id":"PMC_8453306","title":"T-cell chemotactic activity of cytokine LD78: a comparative study with interleukin-8, a chemotactic factor for the T-cell CD45RA+ phenotype.","date":"1993","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8453306","citation_count":20,"is_preprint":false},{"pmid":"38730482","id":"PMC_38730482","title":"Helicobacter pylori disrupts gastric mucosal homeostasis by stimulating macrophages to secrete CCL3.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/38730482","citation_count":19,"is_preprint":false},{"pmid":"1472893","id":"PMC_1472893","title":"Recombinant LD78 protein, a member of the small cytokine family, enhances osteoclast differentiation in rat bone marrow culture system.","date":"1992","source":"Bone and mineral","url":"https://pubmed.ncbi.nlm.nih.gov/1472893","citation_count":19,"is_preprint":false},{"pmid":"36385234","id":"PMC_36385234","title":"Moderate-Intensity Treadmill Exercise Promotes mTOR-Dependent Motor Cortical Neurotrophic Factor Expression and Functional Recovery in a Murine Model of Crush Spinal Cord Injury (SCI).","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36385234","citation_count":19,"is_preprint":false},{"pmid":"8855968","id":"PMC_8855968","title":"BB-10010/MIP-1 alpha in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation.","date":"1996","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8855968","citation_count":19,"is_preprint":false},{"pmid":"23739851","id":"PMC_23739851","title":"CCL3 and CXCL12 production in vitro by dental pulp fibroblasts from permanent and deciduous teeth stimulated by Porphyromonas gingivalis LPS.","date":"2013","source":"Journal of applied oral science : revista FOB","url":"https://pubmed.ncbi.nlm.nih.gov/23739851","citation_count":19,"is_preprint":false},{"pmid":"33584310","id":"PMC_33584310","title":"Systemic Administration of Fibroblast Growth Factor 21 Improves the Recovery of Spinal Cord Injury (SCI) in Rats and Attenuates SCI-Induced Autophagy.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33584310","citation_count":19,"is_preprint":false},{"pmid":"9175116","id":"PMC_9175116","title":"Expression and distribution of CC chemokine macrophage inflammatory protein-1 alpha/LD78 in the human brain.","date":"1997","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/9175116","citation_count":19,"is_preprint":false},{"pmid":"36378535","id":"PMC_36378535","title":"CCL3 in the bone marrow microenvironment causes bone loss and bone marrow adiposity in aged mice.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36378535","citation_count":18,"is_preprint":false},{"pmid":"27894396","id":"PMC_27894396","title":"Ellagic acid ameliorates cuprizone-induced acute CNS inflammation via restriction of microgliosis and down-regulation of CCL2 and CCL3 pro-inflammatory chemokines.","date":"2016","source":"Cellular and molecular biology (Noisy-le-Grand, France)","url":"https://pubmed.ncbi.nlm.nih.gov/27894396","citation_count":18,"is_preprint":false},{"pmid":"38335607","id":"PMC_38335607","title":"The interplay of Cxcl10+/Mmp14+ monocytes and Ccl3+ neutrophils proactively mediates silica-induced pulmonary fibrosis.","date":"2024","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/38335607","citation_count":17,"is_preprint":false},{"pmid":"36550354","id":"PMC_36550354","title":"CCL3 aggravates intestinal damage in NEC by promoting macrophage chemotaxis and M1 macrophage polarization.","date":"2022","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/36550354","citation_count":17,"is_preprint":false},{"pmid":"28847849","id":"PMC_28847849","title":"Otitis Media and Nasopharyngeal Colonization in ccl3-/- Mice.","date":"2017","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28847849","citation_count":16,"is_preprint":false},{"pmid":"23998687","id":"PMC_23998687","title":"CCL2, CCL3 and CCL4 gene polymorphisms in pulmonary tuberculosis patients of South India.","date":"2013","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/23998687","citation_count":16,"is_preprint":false},{"pmid":"35935327","id":"PMC_35935327","title":"CCL3 Promotes Proliferation of Colorectal Cancer Related with TRAF6/NF-κB Molecular Pathway.","date":"2022","source":"Contrast media & molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/35935327","citation_count":15,"is_preprint":false},{"pmid":"35529858","id":"PMC_35529858","title":"Novel Therapeutic Targeting of CCL3-CCR4 Axis Mediated Apoptotic Intesitnal Injury in Necrotizing Enterocolitis.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35529858","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51657,"output_tokens":9349,"usd":0.147603},"stage2":{"model":"claude-opus-4-6","input_tokens":13348,"output_tokens":4585,"usd":0.272047},"total_usd":0.41965,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"CCL3 (MIP-1α) is required for virus-induced inflammatory responses in vivo: CCL3-null mice are resistant to Coxsackievirus-induced myocarditis and show reduced pneumonitis with delayed viral clearance after influenza infection, demonstrating CCL3 is an essential mediator of inflammatory cell recruitment during viral infection.\",\n      \"method\": \"Gene knockout (CCL3-/- mice), viral infection models (Coxsackievirus, influenza), histopathology\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with specific phenotypic readouts, foundational study replicated across two viral models\",\n      \"pmids\": [\"7667639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CCL3 (LD78) signals through a G protein-coupled receptor (identified as HM145/CCR1) to decrease cAMP accumulation and induce calcium influx in stable transfectants, establishing functional receptor coupling.\",\n      \"method\": \"Receptor cloning by PCR, stable transfection, cAMP and calcium flux assays\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro functional reconstitution with stable transfectants, multiple signaling readouts\",\n      \"pmids\": [\"7505609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The LD78beta isoform of CCL3 has a proline at position 2 that confers ~6-fold enhanced binding affinity to CCR5 and ~15–20-fold enhanced affinity to D6 receptor compared to LD78alpha, and displays markedly higher HIV-1 suppressive activity, establishing the N-terminal residue as a critical determinant of receptor binding and antiviral potency.\",\n      \"method\": \"Receptor binding assays, site-directed mutagenesis (Pro2), HIV-1 suppression assays\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with binding assays and functional HIV suppression assay in a single study\",\n      \"pmids\": [\"10364178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CCL3 signals through CCR5 to regulate intratumoral accumulation of macrophages, granulocytes, and fibroblasts; CCL3 stimulates macrophages to express MMP-9 and fibroblasts to express HGF, thereby promoting neovascularization and pulmonary metastasis.\",\n      \"method\": \"CCL3-/- and CCR5-/- gene-deficient mice, bone marrow chimeras, in vitro CCL3 stimulation, MMP-9 and HGF expression analysis\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models plus in vitro validation with specific cellular and molecular readouts\",\n      \"pmids\": [\"18941229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ATP activates P2X7 receptors on microglia, causing dephosphorylation and nuclear translocation of the transcription factor NFAT, which drives CCL3 gene transcription and protein release; NFAT inhibition prevents CCL3 production.\",\n      \"method\": \"Pharmacological P2X7 agonist/antagonist studies, NFAT dephosphorylation assay, nuclear translocation imaging, NFAT inhibitor, siRNA not mentioned but inhibitor experiments in MG-5 cells and primary microglia\",\n      \"journal\": \"Journal of Neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple pharmacological tools and NFAT translocation assay linking P2X7→NFAT→CCL3 axis\",\n      \"pmids\": [\"19014371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structures of CCL3 oligomers in complex with glycosaminoglycans (GAGs) reveal that CCL3 forms high-molecular-weight oligomers, and GAG binding occurs via residues from two partially buried BBXB motifs that combine to form a GAG-binding groove in the CCL3 oligomer; an alternative CCL3 oligomer structure shows conformational changes in CCL3 N-termini that profoundly alter surface properties and dimer–dimer interactions to affect both GAG binding and oligomerization.\",\n      \"method\": \"X-ray crystallography, biophysical analyses (structural determination of GAG-bound CCL3 oligomers)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences USA\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures with functional mutagenesis context, single rigorous structural study\",\n      \"pmids\": [\"27091995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PGE2 inhibits CCL3 and CCL4 expression in dendritic cells via a signaling pathway: EP-2 receptor → cAMP → EPAC → PI3K → PKB → GSK-3, leading to increased DNA binding of the transcriptional repressor CDP (CCAAT displacement protein) to CCL3/CCL4 promoters; CDP knockdown by siRNA confirmed direct regulation of CCL3 transcription.\",\n      \"method\": \"Pharmacological pathway dissection, siRNA knockdown of CDP, EMSA/DNA-binding assays in dendritic cells\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple pathway inhibitors plus siRNA validation establishing direct transcriptional repression mechanism\",\n      \"pmids\": [\"15498767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CCL3 is required for CD8+ T cell differentiation into effector cells during CNS viral infection: CCL3-/- mice have CD8+ T cells primed in lymph nodes that remain CD62L-high, CD25-low, and CCR7+, with reduced CCR5 and CXCR3 expression, impaired cytokine production, and reduced cytolytic activity, indicating CCL3 promotes the transition of primed CD8+ T cells to effector phenotype and their egress to infection sites.\",\n      \"method\": \"CCL3-/- mice, mouse hepatitis virus CNS infection, flow cytometry of T cell phenotypes, cytolytic activity assays\",\n      \"journal\": \"Journal of Virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple orthogonal phenotypic readouts defining CCL3's role in T cell differentiation\",\n      \"pmids\": [\"12634360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MIP-1α/CCL3 is a downstream transcriptional target of FGFR3 and RAS-MAPK signaling in multiple myeloma: FGFR3 inhibition (by kinase inhibitors or siRNA) suppresses CCL3 promoter activity, gene expression, and protein secretion, while ERK1 inhibition in RAS-mutant cells also downregulates CCL3, placing CCL3 downstream of the FGFR3→RAS→MAPK→ERK axis.\",\n      \"method\": \"FGFR3 kinase inhibitors, FGFR3-specific siRNA, FGF ligand stimulation, gene expression arrays, promoter reporter assays, ERK inhibition\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple independent modulators of FGFR3 with promoter assay validation, defining signaling axis\",\n      \"pmids\": [\"16849642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Tristetraprolin (TTP) binds CCL3 mRNA via conserved AU-rich elements and promotes its degradation; TTP-/- macrophages produce excess LPS-induced CCL3; double-knockout CCL3-/-TTP-/- mice show reduced inflammatory arthritis and attenuated atherosclerosis compared to TTP-/- mice, demonstrating TTP is a key post-transcriptional repressor of CCL3 in tissue inflammation.\",\n      \"method\": \"TTP mRNA-binding screen, CCL3-/-TTP-/- double knockout mice, arthritis and atherosclerosis models, plasma CCL3 measurement\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — RNA-binding interaction established, double-KO genetic epistasis with multiple disease models\",\n      \"pmids\": [\"21784977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Neutrophil-derived serine proteases (cathepsin G, elastase, proteinase 3) proteolytically cleave both LD78beta and LD78alpha isoforms of CCL3 at specific sites (Thr16-Ser17, Phe24-Ile25, Tyr28-Phe29, Thr31-Ser32), with cathepsin G preferentially cleaving Phe24-Ile25 and Tyr28-Phe29, and elastase/proteinase 3 cleaving Thr16-Ser17 and Thr31-Ser32; proteolysis of LD78beta abolishes its chemotactic activity.\",\n      \"method\": \"In vitro protease cleavage assays, mass spectrometry, peptide sequencing, serine protease inhibitors, chemotaxis assays; Papillon-Lefevre syndrome patient lysates as controls\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical reconstitution with MS-defined cleavage sites and functional chemotaxis readout\",\n      \"pmids\": [\"15728180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCL3 (MIP-1α) induces migration of GM-CSF-primed human neutrophils via CCR5, with ERK1/2 (but not ERK1 alone) and p38 MAPK as required intracellular signaling components; GM-CSF priming activates ERK-1 enabling CCR5-mediated CCL3 responsiveness in neutrophils.\",\n      \"method\": \"Chemotaxis assays, CCR5 antagonist TAK-779, ERK1/2 and p38 MAPK inhibitors, GM-CSF priming\",\n      \"journal\": \"Cellular Signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibitors defining signaling pathway; single lab study\",\n      \"pmids\": [\"15567066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL3 interacts specifically with CCR1 (not CCR5) to mediate radiation-induced pulmonary inflammation and fibrosis: CCL3-/- and CCR1-/- mice are protected from radiation-induced lung inflammation, fibrosis, and loss of lung function, while CCR5-/- mice are not protected; a small-molecule CCR1 inhibitor also prevented these conditions.\",\n      \"method\": \"CCL3-/-, CCR1-/-, CCR5-/- knockout mice, thoracic irradiation model, CCR1 pharmacological inhibitor, hydroxyproline assays, flow cytometry, lung function measurement\",\n      \"journal\": \"American Journal of Respiratory Cell and Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models plus pharmacological validation, receptor specificity defined by differential KO phenotypes\",\n      \"pmids\": [\"20870892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCL3-mediated neutrophil extravasation requires leukocyte CCR1 and non-leukocyte CCR5; both G protein-receptor coupling and PI3Kγ signaling are essential for CCL3-induced neutrophil responses; β2 and α4 integrins and their counter-receptors ICAM-1 and VCAM-1 are required for CCL3-induced intravascular adherence and transmigration.\",\n      \"method\": \"In vivo microscopy (mouse cremaster muscle), Ccr1-/- and Ccr5-/- mice, cell-transfer techniques, PI3Kγ inhibitor, G protein inhibitor, integrin-blocking antibodies\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo intravital microscopy plus genetic and pharmacological dissection of receptor and signaling requirements\",\n      \"pmids\": [\"22674804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CCL3 selectively mobilizes mature NK cells (mNK) from bone marrow by acting on CCR1-expressing mNK cells and by inhibiting CXCL12-mediated mNK cell retention in vitro; pNK and iNK cells expressing only CXCR4 do not respond directly to CCL3, establishing a stage-specific chemokine receptor regulation of NK cell bone marrow trafficking.\",\n      \"method\": \"In vivo CCL3 administration to C57BL/6 mice, CXCR4 antagonist AMD-3100, in vitro migration assays, flow cytometry of NK cell subsets\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro experiments with stage-specific NK cell populations defining differential responsiveness\",\n      \"pmids\": [\"18227348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL3 is required for activation of alveolar macrophage phagocytic function during Klebsiella pneumoniae pulmonary infection: CCL3-/- mice show an 800-fold higher lung bacterial burden, without defects in leukocyte recruitment, but with significantly lower phagocytic activity of CCL3-/- alveolar macrophages; this effect is mediated via CCR1 rather than CCR5.\",\n      \"method\": \"CCL3-/- and CCR5-/- mice, intratracheal K. pneumoniae infection, CFU counts, macrophage phagocytosis assay\",\n      \"journal\": \"Infection and Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple KO models with mechanistic dissection (phagocytosis assay) showing function beyond chemotaxis\",\n      \"pmids\": [\"11553580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCL3 inhibits osteoblast function via CCR1: CCL3 activates ERK and downregulates the osteogenic transcription factor osterix, suppressing mineralization and osteocalcin production in human bone marrow stromal cells; CCR1 inhibition restores ERK phosphorylation, osterix, and osteocalcin expression in CCL3-treated cells.\",\n      \"method\": \"Primary human bone marrow stromal cells, HS27A cells, ERK phosphorylation assays, osterix/osteocalcin expression, CCR1 small-molecule inhibitor, SCID-hu mouse model\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanistic pathway (CCR1→ERK→osterix) with in vivo validation in SCID-hu mice\",\n      \"pmids\": [\"21403648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL3 inhibits erythropoiesis of HSPCs via CCR1-p38 signaling: CCL3 increases p38 phosphorylation and downregulates the master erythroid transcription factor GATA1; CCR1 antagonist treatment partially recovers erythroid colony formation in the presence of CCL3 or leukemic bone marrow plasma.\",\n      \"method\": \"Colony-forming assays, cytokine array, CCR1 antagonist, p38 phosphorylation assay, GATA1 expression, CCL3 knockdown in AML mouse model\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanistic dissection (CCR1→p38→GATA1) confirmed by CCL3 knockdown in vivo\",\n      \"pmids\": [\"27109512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Elevated CCL3 in the bone marrow of multiple myeloma suppresses erythropoiesis of HSPCs via CCR1/p38 signaling and consequent suppression of GATA1 expression; CCR1 antagonist treatment recovers GATA1 expression and rescues erythropoiesis.\",\n      \"method\": \"CCR1 antagonist, p38 signaling analysis, GATA1 expression in patient-derived HSPCs, large clinical cohort correlation\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway consistent with and extending prior Leukemia paper; single lab\",\n      \"pmids\": [\"33239656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCL3 promotes hepatic stellate cell proliferation and migration in vitro, and CCL3-deficient mice show reduced stellate cell activation and liver immune cell infiltration in two fibrosis models, defining CCL3 as a direct mediator of liver fibrosis.\",\n      \"method\": \"CCL3-/- mice, carbon tetrachloride and methionine/choline-deficient diet fibrosis models, in vitro hepatic stellate cell proliferation and migration assays\",\n      \"journal\": \"PloS One\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro functional assay combined with two in vivo KO models\",\n      \"pmids\": [\"23799074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCL3 deficiency attenuates recruitment of CCR1-expressing CD4+ T cells to the liver during Con A-induced hepatitis and reduces hepatic IFN-γ production; dual CCR1/CCR5 antagonist (Met-RANTES) also reduces CD4+ T cell liver infiltration, demonstrating the CCL3-CCR1 pathway mediates CD4+ T cell-driven hepatic inflammation.\",\n      \"method\": \"CCL3-/- mice, Con A hepatitis model, flow cytometry, met-RANTES CCR1/CCR5 antagonist treatment\",\n      \"journal\": \"European Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mice with pharmacological receptor antagonist validation\",\n      \"pmids\": [\"15368307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IFN-γ is hierarchically required for CCL3-mediated neutrophil recruitment in vivo: CCL3 overexpression alone cannot elicit neutrophil recruitment in the absence of IFN-γ, and IFN-γ receptor-deleted mice show a 5-fold reduction in neutrophil recruitment despite CCR1 expression and ex vivo CCL3 responsiveness on their neutrophils.\",\n      \"method\": \"IFN-γ receptor-/- mice, CCL3 overexpression via viral vector, neutrophil ex vivo migration assays, pneumonia virus of mice infection model\",\n      \"journal\": \"BMC Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic dissection with ex vivo functional controls; single lab\",\n      \"pmids\": [\"19298652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCL3 and CCL2 are required for pelvic pain in experimental autoimmune prostatitis: anti-CCL3 neutralizing antibodies attenuate pain development; CCL3-deficient mice show resistance to maintenance of pelvic pain, while CCR5-/- mice do not, suggesting CCL3 acts through a receptor other than CCR5 for this pain phenotype.\",\n      \"method\": \"CCL3-/- and CCR5-/- mice, neutralizing antibodies, experimental autoimmune prostatitis model, mechanical pain assessment\",\n      \"journal\": \"American Journal of Physiology - Regulatory, Integrative and Comparative Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological approaches defining CCL3 role in pain maintenance\",\n      \"pmids\": [\"22814670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCL3 and P2X7 receptors in the spinal dorsal horn contribute to paclitaxel-induced mechanical allodynia: CCL3 and CCR5 are upregulated in the spinal dorsal horn of paclitaxel-treated rats; intrathecal CCL3-neutralizing antibody prevents and reverses allodynia; P2X7R antagonism also prevents allodynia, consistent with P2X7R-driven CCL3 release from spinal microglia.\",\n      \"method\": \"Rat paclitaxel neuropathy model, intrathecal CCL3-neutralizing antibody, P2X7R antagonist A438079, CCL3/CCR5 mRNA quantification, microglial counts\",\n      \"journal\": \"Molecular Pain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — neutralizing antibody and pharmacological receptor blockade in vivo with mechanistic correlation to P2X7→CCL3 axis established previously in vitro\",\n      \"pmids\": [\"25127716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Central (i.c.v.) administration of CCL3 evokes an integrated febrile response with reduction in tail skin temperature and elevation of PGE2 in CSF; the fever is sensitive to ibuprofen and celecoxib but not to dexamethasone; indomethacin blocks the PGE2 rise but not the fever, indicating CCL3 can induce fever via PGE2-independent mechanisms as well.\",\n      \"method\": \"Intracerebroventricular CCL3 injection in rats, body temperature telemetry, tail skin temperature, CSF PGE2 ELISA, antipyretic drug treatments\",\n      \"journal\": \"Brain Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct pharmacological manipulation in vivo with multiple readouts; single lab\",\n      \"pmids\": [\"16836983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"EBV oncoprotein LMP1 activates JNK signaling to upregulate CCL3 and CCL4 in B cells; autocrine CCL3 and CCL4 are required for LCL survival and growth, as their inhibition by shRNA or neutralizing antibodies suppresses proliferation and induces apoptosis.\",\n      \"method\": \"Cytokine antibody arrays, shRNA knockdown of CCL3/CCL4, neutralizing antibodies, LCL proliferation and apoptosis assays, JNK inhibitor\",\n      \"journal\": \"Journal of Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — shRNA and neutralizing antibody approaches with clear cellular phenotype; single lab\",\n      \"pmids\": [\"23760235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Docetaxel (DTX) induces CCL3 in macrophages and cancer cells by relieving CREB-mediated inhibition of CCL3 via reactive oxygen species accumulation; CCL3 then promotes proinflammatory macrophage polarization via the CCL3-CCR5-p38/IRF5 signaling pathway, facilitating macrophage phagocytosis of breast cancer cells.\",\n      \"method\": \"CCL3-knockout transgenic mouse allograft model, macrophage depletion, RNA sequencing, in vitro co-culture phagocytosis assay, CREB inhibitor, pathway dissection\",\n      \"journal\": \"Journal for Immunotherapy of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vivo and in vitro approaches defining ROS→CREB→CCL3→CCR5→p38/IRF5 mechanistic axis\",\n      \"pmids\": [\"35613826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CCL3 signals through CCR5 to suppress MMP-9 expression in macrophages, thereby attenuating CaCl2-induced aortic aneurysm formation; CCL3-/- and CCR5-/- (but not CCR1-/-) mice show exaggerated aneurysm with augmented macrophage infiltration and MMP-9 expression; CCL3 treatment suppresses PMA-induced MMP-9 in macrophages in vitro.\",\n      \"method\": \"CCL3-/-, CCR5-/-, CCR1-/- mice, CaCl2 and angiotensin II aneurysm models, CCL3 immunoneutralization, in vitro macrophage MMP-9 assay, CCL3 treatment\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple receptor-specific KO lines plus in vivo neutralization and in vitro mechanistic validation defining CCL3-CCR5-MMP-9 axis\",\n      \"pmids\": [\"33239616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LPS-induced CCL3 expression in microglia is regulated by p38 MAPK, ERK1/2, and NF-κB signaling pathways: pharmacological inhibition of each pathway reduces CCL3 protein levels and microglial accumulation in vivo; CCL3 neutralization attenuates microglial accumulation and upregulation of COX-2 and iNOS.\",\n      \"method\": \"In vivo LPS rat brain injury model, p38/ERK1/2/NF-κB inhibitors, anti-CCL3 neutralizing antibody, immunofluorescence, Western blot\",\n      \"journal\": \"Acta Neurobiologiae Experimentalis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological pathway inhibitors with in vivo CCL3 neutralization; single lab\",\n      \"pmids\": [\"28094821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"H. pylori infection stimulates macrophages to secrete CCL3 via the JAK1-STAT1 signaling pathway (STAT1 identified as a direct transcription factor for CCL3 by dual-luciferase and chromatin immunoprecipitation assays); secreted CCL3 disrupts gastric epithelial tight junctions through P38 phosphorylation; neutralizing antibody or CCL3 receptor inhibition rescues tight junction integrity.\",\n      \"method\": \"RT-qPCR, Western blot, ELISA, dual-luciferase reporter assay, chromatin immunoprecipitation, transepithelial electrical resistance, P38 inhibitor, in vivo CCL3 injection in mice\",\n      \"journal\": \"Cell Communication and Signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP and luciferase assays establishing STAT1 as direct CCL3 transcription factor, with downstream P38 pathway and in vivo validation\",\n      \"pmids\": [\"38730482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CCL3 promotes bone marrow stromal cell adipogenesis via a positive feedback loop: CCL3 activates STAT3 to induce C/EBPα expression, and C/EBPα in turn activates CCL3 promoter (facilitated by DNA hypomethylation); CCL3 simultaneously inhibits osteogenic differentiation by activating ERK, which upregulates DKK1 to block β-catenin activity; CCL3 neutralization in vivo rescues trabecular bone loss and bone marrow adiposity in aged mice.\",\n      \"method\": \"CCL3-/- mice, antibody-array serum profiling, in vitro BMSC differentiation assays, STAT3 inhibition, ERK inhibition, DKK1 assay, DNA methylation analysis, in vivo neutralizing antibody treatment\",\n      \"journal\": \"JCI Insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling pathways mechanistically defined (STAT3→C/EBPα and ERK→DKK1→β-catenin) with in vivo genetic and antibody validation\",\n      \"pmids\": [\"36378535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Recombinant CCL3 (LD78α and LD78β) stimulates osteoclast-like cell formation in rat bone marrow cultures in the presence of 1α,25-dihydroxyvitamin D3, and this activity is independent of prostaglandin synthesis, establishing a direct role for CCL3 in osteoclast differentiation.\",\n      \"method\": \"Rat bone marrow culture, recombinant LD78 protein, osteoclast-like cell formation assay, prostaglandin synthesis inhibitor\",\n      \"journal\": \"Bone and Mineral\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — in vitro reconstitution with recombinant protein; single lab foundational study\",\n      \"pmids\": [\"1472893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CCL3 inhibits ATP (BzATP)-induced release of IL-1β from monocytic cells via a CCR1-dependent mechanism involving calcium-independent phospholipase A2 (iPLA2), release of small mediators, and nicotinic acetylcholine receptor subunits α7 and α9 (triple-membrane-passing mechanism); siRNA knockdown of CCR1 or iPLA2 blunts the CCL3 inhibitory effect.\",\n      \"method\": \"U937 monocytic cells, siRNA knockdown of CCR1 and iPLA2, nicotinic receptor antagonists, IL-1β ELISA, BzATP P2X7 agonist stimulation\",\n      \"journal\": \"Mediators of Inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA and pharmacological dissection establishing CCR1→iPLA2→nicotinic receptor axis; single lab\",\n      \"pmids\": [\"28757683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Abnormal mechanical stress on cartilage endplate chondrocytes activates Hippo signaling and Yap1 inhibition, driving CCL3 transcription (YAP1 overexpression directly blocks CCL3 promoter to suppress transcription); released CCL3 recruits osteoclasts and promotes their formation for cartilage endplate remodeling and intervertebral disc degeneration.\",\n      \"method\": \"Transcriptome sequencing, Yap1 knockout in cartilage, Hippo pathway activation/blockade, CCL3 ChIP-promoter analysis, osteoclast differentiation assays, AAV5-Yap1 rescue in vivo\",\n      \"journal\": \"Bone Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter ChIP and in vivo genetic rescue defining Hippo-YAP1→CCL3→osteoclast axis; single study\",\n      \"pmids\": [\"38816384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-21 directly targets and downregulates CCL3 mRNA (validated by dual-luciferase reporter assay); CCL3 downregulation by miR-21 overexpression reduces NF-κB pathway activation (IKKα/β and p65 phosphorylation) and attenuates neonatal hypoxic-ischemic brain damage.\",\n      \"method\": \"Dual-luciferase reporter assay, in vivo gain/loss-of-function (miR-21 overexpression in HIBD rat model), Western blot, RT-qPCR\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase assay establishes direct miRNA-CCL3 interaction; in vivo functional consequences demonstrated\",\n      \"pmids\": [\"32306124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Leukocyte-derived CCL3 mediates neutrophil chemotaxis into atherosclerotic plaques: bone marrow chimeric LDLr-/- mice reconstituted with CCL3-/- bone marrow show 31% reduced lesion formation with significantly attenuated neutrophil adhesion and plaque presence, while plaque macrophage and collagen content are unchanged; CCL3-/- neutrophils show reduced CXCL1 responsiveness.\",\n      \"method\": \"Bone marrow chimeras (CCL3-/- into LDLr-/- mice), atherosclerosis model (Western diet), plaque histology, neutrophil turnover analysis, ex vivo chemotaxis\",\n      \"journal\": \"Arteriosclerosis, Thrombosis, and Vascular Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bone marrow chimera establishes leukocyte-specific CCL3 as key source; cell-specific phenotypic analysis\",\n      \"pmids\": [\"23288165\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL3 (MIP-1α/LD78) is a CC chemokine that signals through G protein-coupled receptors CCR1 and CCR5 to drive directed leukocyte chemotaxis, with receptor specificity determining context-dependent outcomes (e.g., CCR1 for radiation fibrosis and bacterial clearance, CCR5 for metastasis and aneurysm suppression); its N-terminal residues are critical for receptor binding affinity; it forms oligomers that bind glycosaminoglycans via a distinct groove; its mRNA is post-transcriptionally destabilized by tristetraprolin; its transcription is driven downstream of FGFR3-RAS-MAPK/ERK, NF-κB, p38, JAK1-STAT1, and NFAT (via P2X7 receptor), and repressed by PGE2 through an EP2-cAMP-EPAC-PI3K-PKB-GSK3-CDP axis; secreted CCL3 activates macrophages to produce MMP-9, promotes osteoclast differentiation, inhibits osteoblast function via CCR1-ERK-osterix, suppresses erythropoiesis via CCR1-p38-GATA1, and promotes adipogenesis of bone marrow stromal cells via STAT3-C/EBPα while inhibiting osteogenesis via ERK-DKK1-β-catenin; neutrophil-derived serine proteases proteolytically inactivate CCL3 at defined sites to limit inflammation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CCL3 (MIP-1α) is a CC chemokine that orchestrates innate and adaptive immune responses by driving leukocyte chemotaxis, activation, and tissue inflammation through its receptors CCR1 and CCR5, while also regulating bone homeostasis and hematopoiesis. CCL3 signals through CCR1 to activate macrophage phagocytosis, mediate radiation-induced pulmonary fibrosis, suppress erythropoiesis via p38-GATA1, and inhibit osteoblast differentiation via ERK-osterix, whereas CCR5-dependent signaling promotes metastasis-associated macrophage MMP-9 production, proinflammatory macrophage polarization via p38/IRF5, and suppression of aortic aneurysm through MMP-9 downregulation [PMID:18941229, PMID:20870892, PMID:27109512, PMID:21403648, PMID:33239616]. CCL3 forms high-molecular-weight oligomers that bind glycosaminoglycans via a composite groove formed by partially buried BBXB motifs, and its N-terminal residues critically determine receptor affinity and HIV-suppressive potency [PMID:27091995, PMID:10364178]. CCL3 transcription is driven by FGFR3-RAS-MAPK/ERK, NF-κB, p38, JAK1-STAT1, and NFAT pathways and repressed by PGE2 through an EP2-cAMP-EPAC-PI3K-PKB-GSK3-CDP axis; its mRNA is post-transcriptionally destabilized by tristetraprolin and targeted by miR-21, while neutrophil serine proteases proteolytically inactivate secreted CCL3 at defined sites to limit inflammation [PMID:16849642, PMID:15498767, PMID:19014371, PMID:21784977, PMID:15728180, PMID:38730482].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Before CCL3's in vivo role was defined, its capacity to stimulate osteoclast-like cell formation in vitro established it as more than a simple chemoattractant, linking it to bone remodeling.\",\n      \"evidence\": \"Recombinant LD78 protein added to rat bone marrow cultures stimulated osteoclast formation independent of prostaglandin synthesis\",\n      \"pmids\": [\"1472893\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single in vitro system; in vivo relevance to osteoclastogenesis not demonstrated\", \"Receptor mediating osteoclast effect unidentified\", \"Mechanism of CCL3-driven osteoclast differentiation undefined\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identification of CCR1 (HM145) as a functional GPCR for CCL3 established that CCL3 signals through a specific receptor to inhibit cAMP and mobilize calcium, providing the first receptor-coupling framework.\",\n      \"evidence\": \"Stable transfectants expressing cloned CCR1 showed CCL3-induced cAMP decrease and calcium influx\",\n      \"pmids\": [\"7505609\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CCR5 not yet identified as second CCL3 receptor\", \"Downstream signaling beyond cAMP/calcium not mapped\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Genetic ablation of CCL3 demonstrated it is an essential mediator of virus-induced inflammatory cell recruitment in vivo, establishing its non-redundant role in host defense.\",\n      \"evidence\": \"CCL3-knockout mice were resistant to Coxsackievirus-induced myocarditis and showed reduced pneumonitis with delayed influenza viral clearance\",\n      \"pmids\": [\"7667639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor(s) mediating the in vivo phenotype not defined\", \"Whether CCL3 acts beyond chemotaxis (e.g., on effector cell function) was unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Site-directed mutagenesis of the N-terminal proline-2 residue revealed that a single amino acid determines receptor-binding selectivity between CCR5 and D6 and profoundly affects HIV-1 suppressive potency, establishing the N-terminus as the critical receptor-engagement determinant.\",\n      \"evidence\": \"LD78β (Pro2) showed ~6-fold enhanced CCR5 binding and ~15–20-fold enhanced D6 binding versus LD78α, with markedly higher HIV suppression\",\n      \"pmids\": [\"10364178\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for Pro2-enhanced binding not resolved\", \"In vivo relevance of LD78β isoform preference not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The finding that CCL3 activates macrophage phagocytosis during bacterial infection—independent of leukocyte recruitment—established a non-chemotactic effector function for CCL3, mediated specifically through CCR1.\",\n      \"evidence\": \"CCL3-/- mice had 800-fold higher lung bacterial burden without recruitment defects; CCL3-/- alveolar macrophages had reduced phagocytic activity; CCR5-/- mice were unaffected\",\n      \"pmids\": [\"11553580\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway linking CCR1 to phagocytic activation undefined\", \"Whether CCL3 directly enhances killing versus uptake unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"CCL3 was shown to be required not only for chemotaxis but also for the differentiation of primed CD8+ T cells into functional effectors during CNS viral infection, expanding its role to adaptive immune programming.\",\n      \"evidence\": \"CCL3-/- mice had CD8+ T cells stuck in a CD62Lhi/CD25lo/CCR7+ naive-like state with impaired cytokine production and cytolytic activity\",\n      \"pmids\": [\"12634360\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CCL3 acts directly on T cells or indirectly via APCs not resolved\", \"Receptor specificity for T cell differentiation effect unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Dissection of the PGE2 repression pathway revealed a complete signaling cascade (EP2→cAMP→EPAC→PI3K→PKB→GSK3→CDP) that directly represses CCL3 transcription, defining the first negative transcriptional regulatory axis for CCL3.\",\n      \"evidence\": \"Pharmacological pathway dissection and CDP siRNA knockdown in dendritic cells with EMSA confirmation of CDP binding to CCL3 promoter\",\n      \"pmids\": [\"15498767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other transcriptional repressors cooperate with CDP unknown\", \"Relevance to non-DC cell types not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Biochemical identification of specific proteolytic cleavage sites in CCL3 by neutrophil serine proteases defined a post-secretory inactivation mechanism that limits CCL3-driven inflammation at sites of neutrophil degranulation.\",\n      \"evidence\": \"In vitro cleavage by cathepsin G, elastase, and proteinase 3 mapped by mass spectrometry; cleavage abolished chemotactic activity\",\n      \"pmids\": [\"15728180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of proteolytic inactivation not directly tested\", \"Whether truncated fragments have residual or altered bioactivity unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placing CCL3 downstream of FGFR3-RAS-MAPK/ERK signaling in myeloma cells identified CCL3 as a transcriptional effector of oncogenic kinase pathways, explaining elevated CCL3 in FGFR3-driven malignancy.\",\n      \"evidence\": \"FGFR3 kinase inhibitors, FGFR3 siRNA, and ERK inhibition all suppressed CCL3 promoter activity and protein secretion in myeloma cells\",\n      \"pmids\": [\"16849642\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific transcription factor downstream of ERK that binds CCL3 promoter not identified\", \"Whether RAS-mutant and FGFR3-driven regulation are additive unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Multiple 2008 studies resolved receptor-specific functions: CCL3 acts through CCR5 to promote metastasis-associated macrophage MMP-9 and fibroblast HGF production, through CCR1 to mobilize mature NK cells from bone marrow, and through P2X7-NFAT to drive CCL3 transcription in microglia.\",\n      \"evidence\": \"CCL3-/- and CCR5-/- bone marrow chimeras for metastasis; CCR1-expressing mNK migration assays; P2X7 agonist/NFAT inhibitor experiments in microglia\",\n      \"pmids\": [\"18941229\", \"18227348\", \"19014371\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CCR1 and CCR5 activate distinct signaling cascades in the same cell type not compared\", \"NFAT isoform specificity for CCL3 transcription not determined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Receptor-specificity was further refined when CCR1 (but not CCR5) was identified as the obligate receptor for radiation-induced pulmonary fibrosis, demonstrating that context-specific pathology depends on which receptor CCL3 engages.\",\n      \"evidence\": \"CCL3-/- and CCR1-/- mice were protected from radiation fibrosis while CCR5-/- mice were not; CCR1 small-molecule inhibitor also prevented fibrosis\",\n      \"pmids\": [\"20870892\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell type expressing CCR1 that drives fibrosis not definitively identified\", \"Whether CCL3 is the sole CCR1 ligand responsible not excluded\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Two parallel advances defined CCL3's bone-remodeling and post-transcriptional control: CCL3 inhibits osteoblast differentiation via CCR1→ERK→osterix suppression, and tristetraprolin destabilizes CCL3 mRNA to limit inflammation, as shown by double-knockout genetic epistasis.\",\n      \"evidence\": \"CCR1 inhibitor restored osterix and osteocalcin in CCL3-treated stromal cells; TTP-/-/CCL3-/- double-KO mice had reduced arthritis and atherosclerosis versus TTP-/-\",\n      \"pmids\": [\"21403648\", \"21784977\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TTP regulation of CCL3 is tissue-specific unknown\", \"Additional post-transcriptional regulators beyond TTP not surveyed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Intravital microscopy dissected the cellular choreography of CCL3-induced neutrophil extravasation: leukocyte CCR1 and non-leukocyte CCR5 cooperate, with PI3Kγ and β2/α4 integrins required, establishing the multi-cellular receptor cooperation model.\",\n      \"evidence\": \"Cremaster intravital microscopy with CCR1-/- and CCR5-/- chimeras, PI3Kγ inhibitor, and integrin-blocking antibodies\",\n      \"pmids\": [\"22674804\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Non-leukocyte cell type expressing CCR5 (endothelial vs. perivascular) not resolved\", \"Whether this cooperative model extends beyond cremaster tissue unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Crystal structures of CCL3 oligomers with glycosaminoglycans revealed that oligomerization creates a composite GAG-binding groove from partially buried BBXB motifs, and N-terminal conformational changes modulate dimer–dimer interactions, providing the structural basis for GAG-dependent chemokine presentation.\",\n      \"evidence\": \"X-ray crystallography of GAG-bound CCL3 oligomers with biophysical analyses\",\n      \"pmids\": [\"27091995\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional impact of specific GAG-binding residue mutations on in vivo chemotaxis not tested\", \"Whether different GAG types preferentially bind distinct CCL3 oligomeric states unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"CCL3 was found to suppress erythropoiesis via CCR1→p38→GATA1 downregulation, defining a direct mechanism for anemia in leukemic bone marrow microenvironments.\",\n      \"evidence\": \"Colony-forming assays with CCR1 antagonist and p38 analysis; CCL3 knockdown rescued erythropoiesis in AML mouse model\",\n      \"pmids\": [\"27109512\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CCL3 acts directly on erythroid progenitors versus through niche cells not fully resolved\", \"Interaction between p38-GATA1 and other erythroid regulators not explored\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"CCL3 signaling through CCR5 was shown to suppress MMP-9 in macrophages and protect against aneurysm, revealing a previously unrecognized anti-inflammatory/tissue-protective function through CCR5, contrasting with CCR5's pro-metastatic role in other contexts.\",\n      \"evidence\": \"CCL3-/- and CCR5-/- (but not CCR1-/-) mice had exaggerated aneurysm; CCL3 treatment suppressed PMA-induced MMP-9 in vitro\",\n      \"pmids\": [\"33239616\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling mechanism by which CCR5 suppresses MMP-9 transcription not identified\", \"Whether this protective role extends to other vascular pathologies unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A dual signaling mechanism was established for CCL3 in bone marrow stromal cells: STAT3→C/EBPα promotes adipogenesis (with a C/EBPα→CCL3 promoter positive feedback loop) while ERK→DKK1 inhibits β-catenin-dependent osteogenesis, providing a unified framework for CCL3's role in age-related bone loss.\",\n      \"evidence\": \"CCL3-/- mice, in vitro BMSC differentiation with STAT3/ERK inhibitors, DKK1 assay, DNA methylation analysis, in vivo neutralizing antibody rescue of trabecular bone\",\n      \"pmids\": [\"36378535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this mechanism operates in myeloma bone disease in addition to aging not tested\", \"Epigenetic feedback loop (DNA hypomethylation) mechanism not fully defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"STAT1 was identified as a direct transcription factor for CCL3 downstream of JAK1 in H. pylori-stimulated macrophages, and secreted CCL3 was shown to disrupt epithelial tight junctions via p38, extending CCL3's functional repertoire to barrier disruption.\",\n      \"evidence\": \"ChIP and dual-luciferase reporter confirmed STAT1 binding to CCL3 promoter; transepithelial resistance measurements with p38 inhibitor and in vivo CCL3 injection\",\n      \"pmids\": [\"38730482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT1 cooperates with NF-κB at the CCL3 promoter in this context not tested\", \"Tight junction targets downstream of p38 not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Outstanding questions include how CCR1 and CCR5 activate divergent (sometimes opposing) downstream programs in the same cell type, the structural basis for oligomer-dependent receptor activation in vivo, and whether proteolytic processing generates bioactive CCL3 fragments with distinct receptor selectivity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of CCL3-CCR1 or CCL3-CCR5 signaling complex exists\", \"In vivo relevance of neutrophil protease-mediated CCL3 inactivation not demonstrated\", \"Mechanism by which CCL3 promotes CD8+ T cell effector differentiation (direct vs. indirect) unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 2, 3, 11, 12, 13, 14, 16, 17, 27]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [16, 17, 27, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 3, 5, 10, 14, 15, 29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 7, 13, 15, 20, 21, 35]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3, 11, 12, 16, 17, 26, 27, 29, 30]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CCR1\",\n      \"CCR5\",\n      \"TTP\",\n      \"STAT1\",\n      \"NFAT\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}